Viji Finance Ltd

Trading approvals and listing

• Trading approvals from BSE and NSE for 10,000,000 equity shares issued to non-promoters.
• Face value Rs 1; premium Rs 1.80 per share; issue price Rs 2.80.
• Distinctive numbers from 221000001 to 231000000.
• Issued on preferential basis pursuant to conversion of warrants.
• Listing effective Oct 16, 2026; approvals dated Oct 15, 2026.
• Lock-in period of 18-Apr-2027 for 10,000,000 shares (Annexure I).

Financial highlights

• Q3 2026 total income ₹285.23 L; PAT ₹151.10 L.
• H1 2026 total income ₹492.60 L; PAT ₹264.81 L.
• EPS (continuing & discontinued) basic/diluted ₹0.07.
• Total assets ₹5,649.61 L; cash ₹142.90 L as at 30.09.2026.
• Equity share capital increased to ₹23.10 Cr post preferential allotment.

Revenue details

• Interest income in Q3 2026 ₹121.54 L; Fees ₹155.00 L.
• Total revenue from operations in Q3 2026 ₹276.54 L; H1 ₹407.71 L.

Profitability & costs

• PBT before tax in Q3 2026 ₹201.78 L; H1 ₹354.69 L.
• Tax expense in Q3 2026 ₹50.68 L; PAT ₹151.10 L.
• Total expenses in Q3 2026 ₹83.45 L.

Balance sheet highlights

• Total assets ₹5,649.61 L; loans ₹5,207.31 L; investments ₹74.19 L.
• Borrowings ₹337.53 L; trade payables ₹57.89 L; equity ₹2,310 L; reserves ₹2,769.10 L.

Cash flow

• Operating cash flow: net outflow ₹2,040.70 L in H1 2026.
• Investing: net inflow ₹117.95 L; financing: net inflow ₹99.22 L in overall cash.

Capital actions

• Preferential allotment of 8.85 crore warrants; equity increased to ₹23.10 Cr.

Financial results approved

• Approved unaudited standalone quarterly and half-year results ended 30 September 2026 with assets, liabilities and cash flow.
• Limited Review Report obtained with unmodified opinion.
• Results to be filed in XBRL and uploaded on company and stock exchange websites.

Auditor appointment via postal ballot

• Notice seeking shareholder approval for appointment of M/s DDS & Associates as Statutory Auditors to fill casual vacancy.
• Board authorized Company Secretary to conduct postal ballot and related notices.

Capital raise and share capital increase

• Preferential allotment: 8,85,00,000 warrants allotted to 19 investors on 16 June 2026.
• Balance payment led to allotment of 8,85,00,000 equity shares, increasing paid-up capital to ₹23.10 crore.

Trading approvals and listing

• Trading approvals received from BSE and NSE for 29.5 million shares issued to non-promoters on a preferential basis.
• Distinctive numbers range 191,500,001 to 221,000,000 across six tranches.
• Trading admitted effective 29 September 2026; listing confirmed.
• Lock-in across six tranches totaling 29.5 million shares until 31-Mar-2027.

Viji Finance Limited: Trading Window closed from Oct 1, 2026 for the quarter and half-year ended September 30, 2026; Trading Window shall open 48 hours after un-audited Financial Results for the quarter and half year ended September 30, 2026, become generally available i.e. declaration of these Results to the Stock Exchanges.

Listing approvals and next steps

• BSE and NSE have granted listing approvals for 29.5 million preferential equity shares.
• Shares issued at Re 1 with Rs 1.80 premium; distinctive numbers 191500001 to 221000000.
• Allotted to non-promoters/public on a preferential basis upon conversion of warrants.
• Trading approval will be granted only after depository confirmation and credit to beneficiaries.
• NSE in-principle listing approval granted; final listing contingent on depository confirmation and ICDR compliance.
• Company to file trading approvals within seven working days from listing approval.
• Regulatory notes require ICDR compliance; XBRL filing if shareholding changes exceed 2%.
• Date of grant: 11 September 2026.

Listing approvals and share details

• Receipt of BSE and NSE approvals for 29.5 million shares issued on preferential basis.
• Face value Re 1, premium Rs 1.80; distinctive numbers 191,500,001 to 221,000,000.
• Shares allotted to non-promoters/public on conversion of warrants.
• Trading approval expected after depository credit confirmations and related formalities.
• Compliance with ICDR Regulation 167; XBRL filing if paid-up capital changes exceed 2%.
• NSE in-principle listing approval granted; final listing upon depository confirmation.
• SEBI circular requires trading application within seven working days from listing approval.

Auditors appointment

• To fill casual vacancy created by the resignation of Dharmendra K Agarwal & Co.
• Recommend appointing DDS & Associates as Statutory Auditors to fill the vacancy.
• Subject to member approval within 3 months under Section 139(8) of the Companies Act, 2013.
• Term of office from appointment until the conclusion of the next AGM.

Auditor Appointment

• Board recommended DDS & Associates as Statutory Auditors to fill the casual vacancy.
• Appointment subject to Members' approval under Section 139(8) of the Companies Act, 2013.
• Date of appointment recommended: 02 September 2026.
• Term until the next AGM, subject to Members' approval.
• Resignation of Dharmendra K Agarwal & Co created the casual vacancy.